General Biotechnology

Pharma doesnt lose to generics because it cant innovate.
It loses because it doesnt move fast enough on what innovation looks like after the first approval.
Reformulation is often treated like a tactical footnotesomething companies do only when the pat…

Stop Copying Molecules. Patent the Delivery.
Drug developers have a familiar instinct: find the active ingredient everyone wants, then rush to be the next to claim the moleculefast, cheap, and defensible in court. Its understandable. But its also inc…

Generic Gold Rush: Predicting Drug Price Erosion After Patent Expiry
Patent expiry is often sold as a simple story: once exclusivity ends, generics rush in, prices fall, budgets improve. Reality is rarely that clean. The generic gold rush can be fast, …

Branded-generic launches are usually treated like market eventsnew SKUs hit the shelf, prescriptions shift, revenue gets reassessed.
But from a competitive intelligence perspective, the real opportunity starts earlier: when you can track the launch, ti…

The Unique Mechanism of Ozempic for Weight Loss: A Comprehensive Guide What is Ozempic? Ozempic, also known as semaglutide,… https://www.Drugchatter.com/chat/37116/what-unique-mechanism-does-ozempic-use-for-weight-loss/

The Unique Mechanism of Ozempic for Weight Loss: A Comprehensive Guide What is Ozempic? Ozempic, also known as semaglutide,… https://www.Drugchatter.com/chat/37116/what-unique-mechanism-does-ozempic-use-for-weight-loss/

The Unique Mechanism of Ozempic for Weight Loss: A Comprehensive Guide What is Ozempic? Ozempic, also known as semaglutide,… https://www.Drugchatter.com/chat/37116/what-unique-mechanism-does-ozempic-use-for-weight-loss/

Patent thickets arent just a legal nuisancetheyre a market mechanism that quietly delays the moment generics and biosimilars can compete.
Heres the part most people miss: the expiration date you see in headlines is often not the same date that decides …

The Purple Book Was Never Designed to Answer the Question Drugmakers Actually Ask
For anyone trying to assess biosimilar competition, the Purple Book is often the first stop.
It is also where many patent strategies begin to go wrong.
The FDAs Purple Bo…

The next billion-dollar patent fight in pharma may not be over a drug. It may be over the test that determines who gets it.
For years, pharmaceutical companies treated diagnostics as adjacent to the main event: useful for clinical development, importan…